Based on recent market data as of July 2025, stocks to watch include:
- High performers: Palantir (PLTR) up 80.2% YTD, NRG Energy (NRG) 78.0%.
- Growth tech: Super Micro (SMCI) with 38% earnings growth, SoundHound AI (31.6% revenue growth).
- Penny picks: Tiziana Life Sciences for biotech potential.
DYOR; markets fluctuate. Specific queryBased on recent market data as of July 2025, stocks to watch include:
- High performers: Palantir (PLTR) up 80.2% YTD, NRG Energy (NRG) 78.0%.
- Growth tech: Super Micro (SMCI) with 38% earnings growth, SoundHound AI (31.6% revenue growth).
- Penny picks: Tiziana Life Sciences for biotech potential.
DYOR; markets fluctuate. Specific query?
@twistednico Smaller part of the business for #PETS but #CVSG will be the bigger loser here.
Vet prices review over fears pet owners are being overcharged
https://t.co/hsdfLnh6iw
Today OKYO Pharma Announced First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease. A big milestone for the company. #OKYO $OKYO
https://t.co/yIehp9okjt
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease. Another big step forward towards our imminent phase 2 trial starting $OKYO #OKYO
https://t.co/lOY79BDR84
We are happy to share our new corporate deck on our website today. This includes an exciting update on patient EA2 who has now returned to work part time after being treated with intranasal foralumab.
Full deck: https://t.co/NJpBX1kI3W
$TLSA #MultipleSclerosis#SPMS@MSNewsToday
Foralumab In the May edition of @TheLancetInfDis@TheLancet $TLSA
"Gene expression analysis found changes in gene expression patterns (including NKG7, TGF beB1 and GIMAP7) involved with the anti-inflammatory effects of the drug, not only in COVID-19 patients, but also in a patient with multiple sclerosis, meaning the drug may be used for several diseases."
https://t.co/ZXpj2kG5Vr
Thank you @proactive_NA for the interview about our news today about #Alzheimers. Link to the interview with the chief medical officer, Matthew Davis can be found below. $TLSA
https://t.co/Kn8Z0eQXv0
Today we are happy to announce that we will file an Alzheimer’s IND for Intranasal Foralumab in Q2 2023.
Also an application for a $3m grant will be applied for to support the 2a trial.
$TLSA #Alzheimers#alzheimersdisease#AD
https://t.co/I1clToBpX0
@TizianaLS will start Type 1 #diabetes program using intranasal foralumab (IF). The anti-CD3 mAb's ability to regulate inflammation, #FDA approval of TZIELD & easier administration of IF are drivers.
$TLSA PR: https://t.co/FAo0oVMmRM
@TizianaLS to pursue intranasal foralumab for long COVID.
$TLSA Ph2a trial to start after 4Q23 IND & FDA go-ahead.
https://t.co/2a9BdwciSs
Recent @KFF note on long COVID:
https://t.co/DgZIUNquh4
$TLSA (+4.9% pre) Tiziana Life Sciences (TLSA) to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID - SI
https://t.co/RYcSiOc3dm
⚠️ BREAKING:
Burundi 🇧🇮 quarantines the community of Baziro after an outbreak of a "mysterious disease" resembling hemorrhagic fever appears, killing three.